Introduction to SERMs and Innate Immunity

Selective Estrogen Receptor Modulators (SERMs), such as raloxifene and tamoxifen, have long served as cornerstones in oncology and women's health. However, emerging research indicates their influence extends far beyond hormonal regulation. Recent studies demonstrate that these agents play a pivotal role in the innate immune system. Specifically, they facilitate SERMs macrophage immunometabolic reshaping, which alters how immune cells respond to pathogens. This process is largely independent of traditional estrogen receptor pathways. Instead, it involves a complex interplay of metabolic signaling and antioxidant responses. For clinicians in India, where infectious disease management remains a primary challenge, understanding these non-canonical drug actions is essential. These findings suggest that SERMs could be repurposed as host-directed therapies. By modulating the patient's own immune response, these drugs might enhance pathogen clearance while minimizing inflammatory damage. Consequently, the ability of raloxifene and tamoxifen to induce NRF2 activation and metabolic adaptation represents a significant shift in our therapeutic approach. This reshaping provides a blueprint for managing infections through immunometabolic modulation.

The Role of TLRs in Macrophage Polarization

Macrophages are essential effectors of the innate immune response, relying on Toll-like receptors (TLRs) to sense microbial threats. When these receptors are activated, they initiate a cascade that determines the cell's inflammatory profile. The recent study highlights that SERMs significantly influence this polarization process. By modulating the responses induced by TLR7/8, TLR4, and TLR2, raloxifene and tamoxifen create a unique cytokine signature. Interestingly, they reduce the expression of IL-6, a cytokine often associated with chronic inflammation and systemic damage. Simultaneously, they enhance the production of TNF-α and promote the maturation of IL-1β. This specific pattern suggests that SERMs do not simply suppress the immune system. Rather, they refine it to be more efficient. Furthermore, the repression of IL-6 is particularly pronounced with raloxifene, indicating drug-specific effects within the SERM class. For medical practitioners, this nuanced control of the inflammatory environment is highly relevant. It suggests that these drugs could help prevent the hyper-inflammation seen in severe infections while maintaining the host's ability to fight the invader. Therefore, understanding SERMs macrophage immunometabolic reshaping at the receptor level is crucial for future clinical application.

Molecular Mechanisms: AEBS Inhibition and NRF2 Activation

A primary driver of the observed immune changes is the inhibition of the Anti-Estrogen Binding Site (AEBS). This site is critically involved in cholesterol metabolism, and its blockade leads to significant cholesterol-pathway remodeling. This metabolic shift is not merely a side effect; it is a fundamental part of the immunoregulatory mechanism. Inhibition of AEBS triggers the PI3K-NRF2 signaling axis, which is a master regulator of the cell's antioxidant defenses. Once NRF2 is activated, it migrates to the nucleus to induce genes that protect the macrophage from oxidative stress and metabolic exhaustion. This NRF2-related immunometabolic adaptation is a hallmark of the SERMs macrophage immunometabolic reshaping process. Moreover, the sustained engagement of the NRF2 pathway by raloxifene correlates with its superior ability to restrain IL-6. In the context of the Indian clinical landscape, where metabolic disorders and infections often coexist, this link is particularly important. By targeting the intersection of metabolism and immunity, SERMs offer a sophisticated way to manage inflammation. This mechanism highlights the potential for using metabolic interventions to achieve desirable immune outcomes in various disease states.

Lysosomal Stress and Cytokine Regulation

In addition to metabolic remodeling, raloxifene and tamoxifen induce what researchers term "lysosomal stress." Lysosomes are no longer viewed simply as the cell's waste disposal units; they are dynamic signaling hubs. SERMs cause specific perturbations in lysosomal function that lead to the activation of cathepsin B. This enzyme is a critical component of the inflammasome, which regulates the maturation of IL-1β. Consequently, the SERMs macrophage immunometabolic reshaping involves an increase in IL-1β production, despite a paradoxical reduction in its precursor mRNA levels. This indicates that the drugs exert control at a post-translational level, ensuring a controlled but potent immune signal. Furthermore, there appears to be a functional crosstalk between lysosomal stress and the NRF2 pathway. Inhibiting cathepsin B actually enhances NRF2-target gene responses, suggesting a feedback loop that the cell uses to balance its inflammatory output. For healthcare providers, this underscores the importance of subcellular health in systemic immunity. The ability of SERMs to target the lysosome provides an additional layer of immune modulation that could be leveraged in treating intracellular infections, where lysosomal function is often compromised.

SERMs as Host-Directed Anti-Infective Agents

The concept of host-directed therapy (HDT) is gaining prominence as a strategy to combat antimicrobial resistance. Instead of attacking the pathogen directly, HDT focuses on optimizing the patient's immune response. The findings regarding SERMs macrophage immunometabolic reshaping position drugs like raloxifene and tamoxifen as viable HDT candidates. Since these drugs are already widely used and have established safety profiles, the transition to using them for infectious diseases could be accelerated. This is especially pertinent in India, where the burden of resistant infections like tuberculosis is high. By promoting an integrated immunometabolic reshaping, SERMs prepare macrophages to handle pathogens more effectively. They facilitate a balanced cytokine environment that supports clearance without causing excessive tissue injury. Additionally, the fact that these effects are independent of estrogen receptors means they could potentially be utilized across different patient demographics. However, careful consideration of dosage and timing will be necessary to maximize the anti-infective benefits. As we look for innovative ways to manage difficult-to-treat infections, repurposing known agents like SERMs offers a cost-effective and scientifically sound path forward.

Clinical Implications and Future Outlook

The detailed molecular mapping of SERMs macrophage immunometabolic reshaping provides a solid foundation for future clinical research. By integrating cholesterol-pathway remodeling and lysosomal stress, these drugs elicit a comprehensive change in macrophage behavior. This research not only expands our understanding of SERMs but also highlights the importance of immunometabolism in clinical practice. As we move forward, it is likely that we will see more clinical trials investigating these drugs as adjuncts to standard anti-infective therapy. For clinicians, the takeaway is that the medications we use for one condition often have profound effects on other systems. The crossover between oncology, endocrinology, and infectious disease is a fertile ground for medical innovation. Therefore, staying informed about these non-hormonal pathways is vital for modern medical practice. While further studies are needed to confirm these effects in human subjects, the preclinical data is compelling. The transition toward host-directed strategies represents the next phase of precision medicine. By harnessing the power of SERMs to reshape the immune landscape, we can develop more resilient strategies against the ever-evolving threat of infectious diseases.

Frequently Asked Questions

How do SERMs like raloxifene and tamoxifen affect macrophage cytokine production differently from traditional anti-inflammatory drugs?

Traditional anti-inflammatory drugs typically focus on broad suppression of cytokines. In contrast, SERMs like raloxifene and tamoxifen induce a specific immunometabolic reshaping. They restrain the expression of IL-6 while simultaneously enhancing the maturation of IL-1β and the production of TNF-α. This nuanced modulation helps the host maintain an effective anti-infective response through TLR pathways. It prevents the "cytokine storm" associated with excessive IL-6 without completely disabling the immune system's ability to fight pathogens effectively.

What role does the NRF2 pathway play in the immunomodulatory effects of raloxifene and tamoxifen?

The NRF2 pathway acts as a master regulator of the antioxidant and metabolic response within macrophages. When SERMs inhibit the Anti-Estrogen Binding Site (AEBS), they trigger PI3K-NRF2 activation. This leads to immunometabolic adaptation, protecting the cell from oxidative stress during TLR activation. Raloxifene, in particular, promotes sustained NRF2 engagement, which correlates with stronger IL-6 repression. This mechanism allows the drugs to reprogram the macrophage's inflammatory phenotype through integrated metabolic and redox-related pathways.

Can these findings be applied to the treatment of infectious diseases in clinical practice today?

While these findings are highly promising, they currently represent preclinical evidence for host-directed therapy. The research highlights the potential of repurposing raloxifene and tamoxifen to treat infections by reshaping the host's innate immune response. However, clinicians should wait for results from human clinical trials specifically investigating these anti-infective properties. In India, where antimicrobial resistance is a concern, such host-directed agents could eventually serve as vital adjuncts to standard antibiotic or antiviral treatments in the future.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Sfogliarini C et al. Raloxifene and tamoxifen reshape the immunometabolic phenotype of TLRs-activated macrophages through AEBS inhibition and lysosomal stress. Biomed Pharmacother. 2026 Jun 29. doi: undefined. PMID: 42372357.